CytomX Therapeutics Inc (FRA:6C1)
€ 2.911 -0.031 (-1.05%) Market Cap: 651.10 Mil Enterprise Value: 369.98 Mil PE Ratio: 0 PB Ratio: 2.46 GF Score: 36/100

Q4 2019 CytomX Therapeutics Inc Earnings Call Transcript

Feb 27, 2020 / 10:00PM GMT
Release Date Price: €6.55 (+2.03%)
Operator

Good day, ladies and gentlemen, and welcome to the CytomX Therapeutics Fourth Quarter 2019 and Full-Year Financials Conference Call. (Operator Instructions) As a reminder, this call maybe be recorded. I would now like to introduce your host for today's conference, Christopher Keenan, Vice President of Investor Relations. Chris, you may begin.

Christopher S. Keenan
CytomX Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you, Leigh. Good afternoon, and thank you for joining us. Earlier today, we issued a press release that includes a summary of our recent progress and fourth quarter 2019 and full year financial results. This press release and a recording of this call can be found under the Investors and News section of our website at cytomx.com.

With me today are CytomX' President, Chief Executive Officer and Chairman; Dr. Sean McCarthy, CytomX' Chief Development Officer, Dr. Amy Peterson; and CytomX' Vice President of Finance, Robin Knifsend.

During today's call, we will be making forward-looking statements. Because forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot